CD274 and neoplasm: Second, programmed cell death ligand 1 (PD-L1) is highly expressed in the tumor and immune cells of patients with TNBC, which provides a direct target for ICIs and is closely related to the efficacy of anti-programmed death-1 (PD-1) therapy (Buisseret et al., 2017).